• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American College of Cardiology (ACC) 2021

May 15 - 17, 2021

  1. Dapagliflozin
  2. Rosuvastatin
  3. Verinurad
  4. General/Early CVRM

Html

Mediation Analysis for Dapagliflozin and the Reduction in Hospitalization for Heart Failure in DECLARE-TIMI 58

Html

Clinical Profiles, Medical Therapies, and Outcomes Among Patients Hospitalized for HF Across the Spectrum of Kidney Function: The GWTG-HF Registry

Html

Dapagliflozin attenuates endothelial leak via an apolipoprotein m-dependent pathway

Html

Effects Of Dapagliflozin On Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 - Main Results From The DARE-19 Randomized Trial

Html

Leisure-time physical activity associates favorably with the bioactive lipidome and risk of incident CVD events: Results from the VITamin D and OmegA-3 TriaL (VITAL) and JUPITER trials

Html

Rationale and Design for a Phase 2 trial of Verinurad plus Allopurinol in Patients with Heart Failure with Preserved Ejection Fraction and Hyperuricemia

Html

Efficacy, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: a phase 2a study (FLAVOUR)

Html

The safety and efficacy of single and multiple ascending doses of MEDI6570 in participants with type 2 diabetes mellitus

Html

Cardioprotection and plaque regression with MEDI6012 in acute ST elevation myocardial infarction - primary results of the REAL-TIMI 63B randomized clinical trial

Html

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): long-term follow-up of a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol 

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice